DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) --Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced the appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer (CMO) of the Company, effective May 1, 2024.

宾夕法尼亚州多伊尔斯敦（DOYLESTOWN，Pa），2024年5月2日（Global NEWSWIRE）--Aprea Therapeutics，Inc.（纳斯达克：APRE）（“Aprea”或“公司”），一家专注于通过合成致死率进行精确肿瘤学的临床阶段生物制药公司，今天宣布任命Nadeem Q.Mirza，M.D.，M.P.H.为该公司的首席医疗官（CMO），自2024年5月1日起生效。

Dr. Mirza has been an integral part of the Company’s senior team as a consultant since February, 2023 and will now assume a more central role in leading the Company's development of its expanding clinical pipeline..

自2023年2月以来，Mirza博士一直是公司高级顾问团队的组成部分，现在将在领导公司不断扩大的临床渠道的发展中发挥更重要的作用。。

'Aprea is at a critical point of enriching and expanding its clinical programs. Dr. Mirza has already made significant contributions to Aprea and we welcome him formally as our CMO, strengthening our growing senior management team,” said Dr. Oren Gilad, President and CEO of Aprea. “Dr. Mirza has strong expertise in oncology and drug development, with an exceptional track record that encompasses both development stage and commercial programs.

“Aprea正处于丰富和扩大其临床计划的关键时刻。Mirza博士已经为Aprea做出了重大贡献，我们正式欢迎他担任我们的首席营销官，加强我们不断壮大的高级管理团队，”Aprea总裁兼首席执行官Oren Gilad博士说。“米尔扎博士在肿瘤学和药物开发方面拥有丰富的专业知识，拥有包括开发阶段和商业计划在内的卓越记录。

This strategic appointment comes at a pivotal time for the company, as we expand our clinical pipeline and prepare to advance our second asset APR-1051, a highly selective oral WEE1 inhibitor, into the clinic.”.

这项战略任命正值公司的关键时刻，因为我们正在扩大临床渠道，并准备将我们的第二项资产APR-1051（一种高选择性口服WEE1抑制剂）推向临床。”。

Dr. Mirza commented on his new role, stating, “Having worked alongside the talented team at Aprea Therapeutics as an advisor, I am impressed by Aprea’s approach to drug development and have been closely involved in the current clinical development programs. I am pleased to now manage these efforts from within the company and am committed to Aprea’s mission to be a leader in DNA damage response.

Mirza博士评论了他的新角色，他说：“作为顾问，我与Aprea Therapeutics的天才团队一起工作，我对Aprea的药物开发方法印象深刻，并密切参与了当前的临床开发计划。我很高兴现在能够从公司内部管理这些努力，并致力于Aprea成为DNA损伤反应领导者的使命。

I am particularly excited about the first and only oral macrocyclic ATR inhibitor as well as our highly selective oral WEE1 inhibitor and look forward to overseeing the upcoming clinical program for APR-1051, which has best in class potential.”.

我对第一个也是唯一一个口服大环ATR抑制剂以及我们的高选择性口服WEE1抑制剂感到特别兴奋，并期待着监督即将到来的APR-1051临床项目，该项目具有同类最佳的潜力。”。

Dr. Mirza has more than 30 years of clinical and developmental experience in solid tumors and hematologic malignancies, having held significant leadership roles at large pharma and biotech companies. His prior experience includes serving as Senior Vice President, Clinical Development at Salarius Pharmaceuticals, from 2020 to 2023, where he oversaw early phase drug development in oncology.

Mirza博士在实体瘤和血液系统恶性肿瘤方面拥有30多年的临床和发展经验，曾在大型制药和生物技术公司担任重要领导职务。他之前的经验包括从2020年到2023年担任Salarius Pharmaceuticals临床开发高级副总裁，负责肿瘤早期药物开发。

From 2018 to 2019, he was Senior Vice President, Corporate Medical Affairs at Verastem Oncology where he oversaw the launch of Copiktra®. From 2015 to 2017, he served as Global Head Hematology and Solid Tumors at Abbvie Oncology where he oversaw the global launch of Venclexta®. From 2013 to 2015, he was Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology where he was responsible for medical affairs programs to support 12 products across several oncology indications.

2018年至2019年，他担任Verastem Oncology公司医疗事务高级副总裁，负责监督Copiktra®的推出。2015年至2017年，他在Abbvie Oncology担任血液学和实体瘤全球负责人，监督Venclexta®的全球推出。从2013年到2015年，他担任赛诺菲肿瘤学北美医学事务副总裁兼主管，负责医学事务计划，以支持多种肿瘤学适应症的12种产品。

Dr. Mirza holds an M.P.H. from the University of Texas at Houston and earned his M.D. from the University of Punjab..

Mirza博士拥有德克萨斯大学休斯顿分校的医学博士学位，并在旁遮普大学获得了医学博士学位。。

In connection with Dr. Mirza’s appointment, the Company's Board of Directors granted Dr. Mirza a stock option to purchase an aggregate of 26,920 shares of the Company’s common stock (the “Options”). The Options were granted outside of the Company’s 2019 Equity Incentive Plan (the “Plan”) as a material inducement to Dr.

关于Mirza博士的任命，公司董事会授予Mirza博士股票期权，以购买公司普通股总计26920股（“期权”）。这些期权是在公司2019年股权激励计划（“计划”）之外授予的，作为对Dr。

Mirza accepting the Company’s offer of employment in accordance with Nasdaq Listing Rule 5635(c)(4)..

Mirza根据纳斯达克上市规则5635（c）（4）接受公司的雇佣要约。。

The Options have an exercise price of $5.25 per share, which is equal to the closing price of the Company’s common stock on May 1, 2024. The Options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of the grant date and then in equal, monthly installments for 36 months thereafter, subject to Dr.

期权的行权价格为每股5.25美元，相当于该公司2024年5月1日普通股的收盘价。期权的期限为十年，授予期限为四年，在授予日期的一周年纪念日授予25%的原始股份，然后在此后的36个月内等额分期付款，但须符合Dr。

Mirza’s continued service to the Company through the applicable vesting dates..

Mirza在适用的授予日期内继续为公司提供服务。。

The Company's Board of Directors also granted Dr. Mirza 6,730 restricted stock units (the “RSUs”). The RSUs were granted outside of the Plan as a material inducement to Dr. Mirza accepting the Company’s offer of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs shall vest over three years with one-third of the RSUs vesting on each yearly anniversary of the grant date, subject to Dr.

公司董事会还授予Mirza博士6730个限制性股票单位（“RSU”）。根据纳斯达克上市规则5635（c）（4），作为Mirza博士接受公司雇佣要约的重大诱因，在计划之外授予了RSU。根据Dr。

Mirza’s continued service to the Company through the applicable vesting dates..

Mirza在适用的授予日期内继续为公司提供服务。。

About Aprea

关于Aprea

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications.

Aprea Therapeutics，Inc.是一家临床阶段的生物制药公司，总部位于宾夕法尼亚州多伊尔斯敦，专注于通过合成致死率进行精确肿瘤学研究。该公司的主导项目是ATRN-119，一种临床阶段的小分子ATR抑制剂，正在开发用于实体瘤适应症。

Aprea has completed all IND-enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and recently received FDA clearance of its IND. For more information, please visit the company website at www.aprea.com..

Aprea已完成其口服小分子WEE1抑制剂APR-1051的所有IND启用研究，最近已获得FDA对其IND的批准。有关更多信息，请访问公司网站www.Aprea.com。。

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

公司可使用并打算使用其投资者关系网站https://ir.aprea.com/作为披露重大非公开信息和遵守FD法规规定的披露义务的手段。

Forward-Looking Statement

前瞻性声明

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended related to our study analyses, clinical trials, regulatory submissions, and projected cash position.

本新闻稿中包含的某些信息包括《1933年证券法》第27A节（经修订）和《1934年证券交易法》第21E节（经修订）所指的“前瞻性声明”，该节与我们的研究分析、临床试验、监管提交和预计现金状况有关。

We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements.

在某些情况下，我们可能会使用“未来”、“预测”、“相信”、“潜在”、“继续”、“预期”、“估计”、“预期”、“计划”、“打算”、“目标”、“信心”、“可能”、“可能”、“可能”、“可能”、“可能”、“将会”、“应该”或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。

Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

我们的前瞻性陈述基于管理团队当前的信念和期望，以及管理层目前可获得的涉及风险、环境潜在变化、假设和不确定性的信息。除历史事实陈述外，本新闻稿中包含的所有陈述均为前瞻性陈述，包括关于我们开发、商业化和实现市场接受我们当前和计划中的产品和服务的能力的陈述，我们的研究和开发工作，包括时间考虑因素和其他有关我们的业务战略、资本使用、运营结果和财务状况以及未来运营计划和目标的事项。

Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticip.

任何或所有前瞻性陈述都可能被证明是错误的，或者受到我们可能做出的不准确假设或已知或未知风险和不确定性的影响。这些前瞻性陈述存在风险和不确定性，包括但不限于与我们正在进行的临床试验和抗CIP的成功，时机和成本相关的风险。

Investor Contact:

投资者联系人：

Mike Moyer

迈克·莫耶

LifeSci Advisors

LifeSci顾问

mmoyer@lifesciadvisors.com

mmoyer@lifesciadvisors.com